Cargando…

Prospective analysis of clinically significant prostate cancer detection with [(18)F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study

PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging method for localizing primary prostate cancer (PCa) and for guiding targeted prostate biopsies. [(18)F]DCFPyL positron emission tomography combined with MRI (PSMA-PET/MRI) might be of additional value to locali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodar, Yves J. L., Zwezerijnen, Ben G. J. C., van der Voorn, Patrick J., Jansen, Bernard H. E., Smit, Ruth S., Kol, Sabrine Q., Meijer, Dennie, de Bie, Katelijne, Yaqub, Maqsood, Windhorst, Bert A. D., Hendrikse, Harry N. H., Vis, André N., Oprea-Lager, Daniela E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940822/ https://www.ncbi.nlm.nih.gov/pubmed/34725727 http://dx.doi.org/10.1007/s00259-021-05604-9

Ejemplares similares

Cylindroma, an uncommon presentation on (18)F-DCFPyL PET/CT
por: Koene, B. P. F., et al.
Publicado: (2020)

Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020)

Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
por: Bodar, Y. J. L., et al.
Publicado: (2020)

Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
por: Jansen, B. H. E., et al.
Publicado: (2020)

Management impact of (18)F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
por: Meijer, Dennie, et al.
Publicado: (2021)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
por: Wondergem, M., et al.
Publicado: (2019)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

Higher Preoperative Maximum Standardised Uptake Values (SUV(max)) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [(68)Ga]Ga-PSMA-11 and [(18)F]DCFPyL Positron Emission Tomography/Computed Tomography
por: de Bie, Katelijne C. C., et al.
Publicado: (2023)

A Pilot Study of (18)F-DCFPyL PET/CT or PET/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions
por: Liu, Yachao, et al.
Publicado: (2021)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

The differential diagnostic value of dual-phase (18)F-DCFPyL PET/CT in prostate carcinoma
por: Tian, Aijuan, et al.
Publicado: (2022)

Short-duration dynamic [(18)F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [(18)F]DCFPyL PET/MR at 120 minutes
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
por: Mesci, Aruz, et al.
Publicado: (2023)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

[(18)F]DCFPyL PET/CT versus [(18)F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study
por: Oprea-Lager, Daniela-Elena, et al.
Publicado: (2023)

Uptake of [(18)F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies
por: Rowe, Steven P., et al.
Publicado: (2015)

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of (18)F-DCFPyL PET/CT Restaging
por: Liu, Wei, et al.
Publicado: (2020)

Non-prostate cancer tumours: incidence on (18)F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients
por: Perry, Elisa, et al.
Publicado: (2022)

(18)F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
por: Metser, Ur, et al.
Publicado: (2022)

The diagnostic performance of (18)F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis
por: Pang, Wenyang, et al.
Publicado: (2023)

Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [(18)F]DCFPyL-PET: comparison to [(18)F]fluorocholine-PET
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
por: Roy, Jyoti, et al.
Publicado: (2021)

A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems
por: Oprea-Lager, Daniela E., et al.
Publicado: (2015)

Assessment of (18)F-DCFPyL PSMA PET/CT and PET/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability
por: Lawrence, Edward M., et al.
Publicado: (2023)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

PSA-Stratified Performance of [(18)F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy
por: Harsini, Sara, et al.
Publicado: (2022)

[(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
por: Glicksman, Rachel M, et al.
Publicado: (2020)

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

(18)F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center
por: Metser, Ur, et al.
Publicado: (2021)

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
por: Zhou, Shuoming, et al.
Publicado: (2022)

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis
por: Sun, Jiale, et al.
Publicado: (2021)

The Impact of (18)F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT
por: Phillips, Ryan M., et al.
Publicado: (2017)

Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of (18)F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma
por: Mena, Esther, et al.
Publicado: (2022)

Comparative study of (18)F-DCFPyL PET/CT and (99m)Tc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer
por: Hu, Xiongjian, et al.
Publicado: (2023)

Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [(18)F]DCFPyL PET/CT in prostate cancer men
por: Subramanian, Kritika, et al.
Publicado: (2023)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

Intra-patient comparison of physiologic (68)Ga-PSMA-11 and (18)F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay
por: Osman, Medhat M., et al.
Publicado: (2021)

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer
por: Bodar, Yves J.L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i5cnsct789gavm31bea0nbbi8h